Product Pathways - Growth Factors/Cytokines
Human Platelet-Derived Growth Factor AA (hPDGF-AA) #8913
Recombinant human PDGF-AA (hPDGF-AA) Ser87-Thr211 (Accession #NP_002598) was produced in E. coli at Cell Signaling Technology.
Recombinant hPDGF-AA does not have a Met on the amino terminus and has a calculated MW of 14,305. DTT-reduced protein migrates as an 18 kDa polypeptide and the non-reduced cystine-linked homodimer migrates as a 34 kDa protein. The expected amino-terminal SIEEA of recombinant hPDGF-AA was verified by amino acid sequencing.
>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant hPDGF-AA. All lots are greater than 98% pure.
The bioactivity of recombinant hPDGF-AA was determined in a NIH/3T3 proliferation assay. The ED50 of each lot is between 4-12 ng/ml.
The purity of recombinant hPDGF-AA was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant hPDGF-AA and staining overnight with Coomassie Blue.
The proliferation of NIH/3T3 cells treated with increasing concentrations of hPDGF-AA was assessed. After 24 hr treatment, cells were labeled with BrdU for 4 hrs. BrdU incorporation was determined by ELISA and the OD450-OD650 was determined.
Western blot analysis of extracts from NIH/3T3 cells untreated or treated with hPDGF-AA for 10 minutes, using Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb #4060 (upper) and Akt1 (C73H10) Rabbit mAb #2938 (lower).
Less than 0.01 ng endotoxin/1 μg hPDGF-AA.
With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg hPDGF-AA. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.
PDGF-AA is integrally involved in embryonic development, angiogenesis and organogenesis and induces fibroblast proliferation and migration (1,2). PDGF-AA is produced by epithelial, muscle, osteosarcoma and neuronal progenitor cells (1,3). Active PDGF-AA is formed through intracellular proteolytic cleavage of a large precursor. PDGF-AA is also concentrated in the extracellular matrix through alternative splicing that generates an extended carboxy-terminal that binds components of the extracellular matrix. The carboxy-terminal stretch is removed extracellularly to generate mature PDGF-AA (1,2). PDGF-AA binding to the PDGFR-α activates the receptor tyrosine kinase (1). PDGF-AA-induced signaling is through the Ras-MAPK, PI3K/AKT and PLCγ pathways (1). Dysregulation of PDGF-AA expression and/or signaling is often associated with cancer and fibrotic disorders (1).
- Andrae, J. et al. (2008) Genes Dev 22, 1276-312.
- Hoch, R.V. and Soriano, P. (2003) Development 130, 4769-84.
- Siegbahn, A. et al. (1990) J Clin Invest 85, 916-20.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.